ALK and Torii's SLIT for Japanese cedar tree pollen rhinitis achieves positive Phase II/III results

Danish allergy specialist ALK-Abello’s Japanese partner, Torii Pharmaceutical (TSE: 4551), has reported positive results from its Phase II/III trial of its sublingual allergy immunotherapy tablet (SLIT) for Japanese cedar tree pollen allergic rhinitis.

It met its primary efficacy endpoint, which was statistically-significant improvement in the Total Combined Rhinitis Score, compared with patients who received placebo. The trial demonstrated that the SLIT reduced symptoms of Japanese cedar pollen allergy rhinitis, was well-tolerated and had a favorable safety profile.

Jens Bager, president and chief executive, said: “These results mark another step on our journey towards globalizing ALK’s portfolio of SLIT-tablets. Our partnership with Torii continues to progress rapidly and we are getting closer to a launch of these products in the world’s second largest pharmaceutical market.”